20 Nov 2009 03:00 AM
Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripiprazole), Europe
The European Medicines Agency has been formally notified by Otsuka Pharmaceutical Europe Ltd of its decision to withdraw its application for an extension of indication for the centrally authorised medicine Abilify (aripiprazole) tablets, orodispersible tablets and oral solution.
Abilify was expected to be used in the treatment of major depressive episodes, as adjunctive therapy, in patients who have had an inadequate response to previous treatment with antidepressants.
Abilify was first authorised in the European Union on 4 June 2004. It is currently indicated for the treatment of schizophrenia and for the treatment and prevention of manic episodes in bipolar I disorder…
Abilify was expected to be used in the treatment of major depressive episodes, as adjunctive therapy, in patients who have had an inadequate response to previous treatment with antidepressants.
Abilify was first authorised in the European Union on 4 June 2004. It is currently indicated for the treatment of schizophrenia and for the treatment and prevention of manic episodes in bipolar I disorder…
